Cellastra is Pioneering Scar Prevention

At Tissue Sites after Pulmonary Infections/Fibrosis, Burns, and Surgery

Cellastra is using proprietary AAV Technology to enable targeted production of antiscarring peptides

Now seeking qualified investors and development partners

Please see our Technology section for unique opportunities.

Cellastra News

CELLASTRA INC.

02/17/2025

Cellastra One Page Overview: 🔗

Corporate Presentation: 🔗

CELLASTRA INC.

11/18/2024

Cellastra Appoints Emma Ye to the Executive Team

Young Scientist and Entrepreneur promoted to Scientific Adviser, Communications: 🔗

CELLASTRA INC.

02/06/2024

Cellastra Receives US Patent for Recombinant Gene Vectors Encoded to Regulate Endogenous Production of Anti-Scarring/Adhesion Lactoferrin Biomolecules.

a human lactoferrin protein or a sub-peptide thereof: 🔗